Sherbrooke Park Advisers LLC Altimmune, Inc. Put Options Transaction History
Sherbrooke Park Advisers LLC
- $215 Billion
- Q3 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ALT
# of Institutions
194Shares Held
40.1MCall Options Held
3.82MPut Options Held
2.8M-
Vanguard Group Inc Valley Forge, PA6.37MShares$26.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.32MShares$22.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.6MShares$15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.13MShares$8.89 Million0.37% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$8.41 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $204M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...